🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆
Clinical Trials in South Korea / NCT07400458
Recruiting Not applicable

Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration

NCT07400458 · tracked via the Priya Life Science South Korea tracker
Sponsor
Pharmicell Co., Ltd
Phase
Not applicable
Started
2022-03-03
Last updated
2026-02-10

Condition(s) studied

Acute Myocardial Infarction

Investigational drug(s) / intervention(s)

Hearticellgram-AMI

Hearticellgram-AMI: Patients who had administered Hearticellgram-AMI.

Study summary

This Long-term follow-up is designed to evaluate the safety of patient with Acute Myocardial Infarction who had administered Hearticellgram-AMI.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Those who had administered Hearticellgram-AMI 2. Those who voluntarily agreed in writing to participate in this investigation Exclusion Criteria: \-

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
KIMHYUNSOO Clinic Seoul Gangnam Recruiting

More Pharmicell Co., Ltd. trials in South Korea

Long-Term Follow-up of Patients With Chronic Kidney Disease Treated With Cellgram-CKD Active, not recruiting
Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis Recruiting
Long-Term Follow-up of Patients With Alcoholic Liver Cirrhosis Treated With Cellgram-LC Recruiting
Safety Follow-up Study of Cellgram-ED in Post-Radical Prostatectomy Erectile Dysfunction Recruiting

Other trials for the same condition

Acute Myocardial Infarction in Cancer Patients Active, not recruiting
HOST - DAPT Duration According the Bleeding Risk Active, not recruiting
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Enrolling by invitation
Ticagrelor De-escalation Strategy in AMI Patients Recruiting
Revascularization Strategy of Multivessel Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Veno-arterial Extracorporeal Membrane Oxygenator Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07400458 on ClinicalTrials.gov ↗ ← All trials in South Korea